Drugs for Human Herpesvirus 8 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 142)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Vincristine |
Approved, Investigational |
Phase 4 |
|
2068-78-2, 57-22-7 |
5978 |
Synonyms:
(+)-Vincristine
22-Oxovincaleukoblastin
22-oxo-Vincaleukoblastine
22-Oxovincaleukoblastine
28379-27-3
57-22-7
AC1L1LJC
C07204
C46H56N4O10
CCRIS 5763
Cellcristin
CHEBI:28445
CID5978
Citomid
D08679
DB00541
EINECS 200-318-1
Farmistin
HMS2090E19
HSDB 3199
Indole alkaloid
LCR
Leucristine
Leurocristine
Lilly 37231 (1:1 sulfate salt)
Liposomal Vincristine
LS-228
Marqibo
NCGC00163700-01
NCI60_026703
NCI-C04864
NSC-67574
Onco TCS
Oncovin
Oncovin (1:1 sulfate salt)
Oncovine
|
Onkocristin
PFS, Vincasar
Sulfate, vincristine
Tecnocris
Tecnocris (TN)
UNII-5J49Q6B70F
VCR
VIN
Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine
Vincasar
Vincasar (1:1 sulfate salt)
Vincasar PFS
Vincrex
Vincrex (1:1 sulfate salt)
Vincristin
Vincristin bristol
Vincristin medac
Vincristina
Vincristina [DCIT]
vincristine
Vincristine
Vincristine (INN)
Vincristine [INN:BAN]
Vincristine sulfate
Vincristine Sulfate
Vincristine Sulfate PFS
Vincristinum
Vincristinum [INN-Latin]
Vincrisul
Vincrstine
Vincrystine
Vinkristin
Vintec
Z-D-Val-lys(Z)-OH
Z-D-Val-Lys(Z)-OH
|
|
2 |
|
Bleomycin |
Approved, Investigational |
Phase 4 |
|
11056-06-7 |
5360373 |
Synonyms:
(betaR)-N(alpha)-{[6-amino-2-((1S)-3-amino-1-{[(2S)-2,3-diamino-3-oxopropyl]amino}-3-oxopropyl)-5-methylpyrimidin-4-yl]carbonyl}-beta-{2-O-[3-O-(aminocarbonyl)-alpha-D-mannopyranosyl]-alpha-L-gulopyranosyloxy}-N-[(1R,2S,3S)-5-({(1S,2R)-1-[({2-[4-({[3-(dimethylsulfonio)propyl]amino}carbonyl)-2,4'-bi-1,3-thiazol-2'-yl]ethyl}amino)carbonyl]-2-hydroxypropyl}amino)-3-hydroxy-4-methyl-5-oxopentan-2-yl]-L-histidinamide
11056-06-7
11116-31-7
1400-95-9
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[3-[4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
37208-04-1
37293-16-6
37353-43-8
9041-93-4
9041-93-4 (sulfate (salt))
AC1L9UFF
AC1NSEJD
AC1NUTOQ
Almirall brand OF bleomycin sulfate
Bellon brand OF bleomycin sulfate
Bellon, bléomycine
Blanoxan
Blenoxane
Bleo
Bleo cell
Bleo-cell
BLEOcell
Bleocin
Bleogin
Bleolem
Bleomicin
Bleomicina
Bleomicina [INN-Spanish]
bleomycin
Bleomycin
Bleomycin a(2)
Bleomycin A(2)
bleomycin a2
Bleomycin a2
Bleomycin A2
Bleomycin A2 & Bleomycin B2.
Bleomycin b(2)
Bleomycin B(2)
Bleomycin b2
Bleomycin B2
Bleomycin sulfate
|
Bleomycin sulphate
Bleomycine
Bleomycine [INN-French]
Bléomycine bellon
Bleomycins
Bleomycinum
Bleomycinum [INN-Latin]
Bleomycinum mack
BLM
Bristol myers squibb brand OF bleomycin sulfate
Bristol-myers squibb brand OF bleomycin sulfate
Bull brand OF bleomycin sulfate
C06854
C55H85N17O21S3
C55H86N17O21S3
CCRIS 2754
Cell pharm brand OF bleomycin sulfate
CHEBI:3139
CHEMBL403664
CID456190
CID5360373
CID5460769
DB00290
EINECS 234-356-5
HSDB 3208
Lemery brand OF bleomycin sulfate
LMPK14000006
LS-44860
LS-524
Lundbeck brand OF bleomycin sulfate
Mack brand OF bleomycin sulfate
Mack, bleomycinum
N(1)-[3-(dimethylsulfonio)propyl]bleomycinamide
N1-(3-(Dimethylsulfonio)propyl)bleomycinamide
NDC 0015-3010
NSC 125066
Pingyangmyvin A2
STOCK1N-74760
Sulfate, bleomycin
UNII-13M89UEA7W
UNII-40S1VHN69B
Zhengguangmycin A2
Zhengguangmycin A2 [Chinese]
|
|
3 |
|
Doxorubicin |
Approved, Investigational |
Phase 4 |
|
23214-92-8 |
31703 |
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-hydroxydaunomycin
14-Hydroxydaunomycin
14-hydroxydaunorubicine
14-Hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
adiblastine (hydrochloride salt)
ADM
ADR
adr iablatina (hydrochloride salt)
Adriablastin
Adriablastine
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin semiquinone
Adriamycin Semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (hydrochloride salt)
Adriblastina (TN)
Adriblastine
adriblatina (hydrochloride salt)
Adrimedac
Aerosolized Doxorubicin
Baxter brand OF doxorubicin hydrochloride
Bedford brand OF doxorubicin hydrochloride
BPBio1_000502
BRD-K92093830-003-04-3
Bristol-myers squibb brand OF doxorubicin hydrochloride
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
Caelyx
CCRIS 739
Cell pharm brand OF doxorubicin hydrochloride
CHEBI:28748
CHEMBL179
CID31703
Columbia brand OF doxorubicin hydrochloride
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
Doxil
Doxo
Doxo cell
Doxo-cell
Doxolem
doxorubicin
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
|
Doxorubicin HCl
Doxorubicin hexal
Doxorubicin hydrochloride
Doxorubicin Hydrochloride
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin NC
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicina ferrer farm
Doxorubicina funk
Doxorubicina tedec
Doxorubicine
Doxorubicine [INN-French]
Doxorubicine baxter
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicinum
Doxorubicinum [INN-Latin]
Doxotec
DOX-SL
EINECS 245-495-6
Elan brand OF doxorubicin hydrochloride
Farmablastina (hydrochloride salt)
Farmiblastina
Ferrer brand OF doxorubicin hydrochloride
FI 106
Hexal brand OF doxorubicin hydrochloride
HMS2089H06
HSDB 3070
Hydrochloride, doxorubicin
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
Kenfarma brand OF doxorubicin hydrochloride
Lemery brand OF doxorubicin hydrochloride
LMPK13050001
LS-1029
LS-165655
Medac brand OF doxorubicin hydrochloride
MLS000759533
Myocet
NChemBio.2007.10-comp13
nchembio809-comp5
NCI-C01514
NDC 38242-874
Neocorp brand OF doxorubicin hydrochloride
NIOSH/JT9100000
NSC 123127
Onkodox
Onkoworks brand OF doxorubicin hydrochloride
Pfizer brand OF doxorubicin hydrochloride
Prasfarma brand OF doxorubicin hydrochloride
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Ribodoxo
Ribosepharm brand OF doxorubicin hydrochloride
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
Tedec meiji brand OF doxorubicin hydrochloride
ThermoDox
TLC D-99
Triferric doxorubicin
UNII-80168379AG
Urokit doxo cell
Urokit doxo-cell
|
|
4 |
|
Efavirenz |
Approved, Investigational |
Phase 4 |
|
154598-52-4 |
64139 |
Synonyms:
(-)-6-CHLORO-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
(-)-Efavirenz
(4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one
(4S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
(4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one
(4S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
(S)-6-Chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-ben
(S)-6-chloro-4-(Cyclopropylethynyl)-1,4-dihydro-(S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
(S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
(S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
(S)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
(S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
(S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[D][1,3]oxazin-2-one
154598-52-4
1ikv
1ikw
2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)- (9
6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one
6-Chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[D][1,3]oxazin-2-one
AC-19049
AC1L20IX
BIDD:GT0383
Bristol-myers squibb brand OF efavirenz
C08088
C14H9ClF3NO2
CHEBI:119486
CHEMBL223228
CID64139
CPD000466351
D00896
DB00625
DB07709
DMP 266
DMP-266
Du pont brand OF efavirenz
efavirenz
Efavirenz
|
Éfavirenz
Efavirenz (JAN/INN)
Efavirenz, (R)-isomer
efavirenz, (S)-isomer
Efavirenz, (S)-isomer
Efavirenzum
EFV
EFZ
Eravirenz
HMS2051J08
HMS2090N16
HSDB 7163
L 743726
L-741211
L-743,726
L-743725
L-743726
LS-173464
Merck sharp and dohme brand OF efavirenz
Met-SDF-1.beta. & Efavirenz
Met-Stromal Cell-derived Factor-1.beta. (Human) & Efavirenz
MLS000759465
MLS001424087
MolPort-003-983-924
NSC742403
SAM001246667
SBB066062
SMR000466351
Stocrin
Strocin (TM)
Sustiva
Sustiva (TM)
Sustiva (TN)
UNII-JE6H2O27P8
United drug brand OF efavirenz
ZINC02020233
zoxazin-2-one
|
|
5 |
|
Lopinavir |
Approved |
Phase 4 |
|
192725-17-0 |
92727 |
Synonyms:
(1S-(1R*(R*),3R*,4R*))-N-(4-(((2,6-Dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetamide
(2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide
(alphaS)-Tetrahydro-N-((alphaS)-alpha-((2S,3S)-2-hydroxy-4-phenyl-3-(2-(2,6-xylyloxy)acetamido)butyl)phenethyl)-alpha-isopropyl-2-oxo-1(2H)-pyrimidineacetamide
1(2H)-Pyrimidineacetamide, N-[(1S,3S,4S)-4-[[(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-alpha-(1-methylethyl)-2-oxo-, (alphaS)- (9CI)
192725-17-0
1mui
2o4s
2q5k
2rkf
2rkg
378, ABT
A 157378
A 157378.0
A-157378.0
A-157378-0
AB1
ABT 157378
ABT 378
ABT-378
ABT-378, LOPINAVIR
ABT-378a-157378-0a-157378.0
AC1L3OPJ
AIDS032937
Aluviran
|
C12871
C37H48N4O5
CHEBI:40456
CHEMBL729
CID92727
D01425
DB01601
Kaletra
Koletra
Lopinavir
Lopinavir (JAN/USAN/INN)
Lopinavir [USAN:INN:BAN]
LPV
LS-173766
MolPort-003-848-410
N-(4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide
N-(4-(((2,6-Dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide
N-{1-BENZYL-4-[2-(2,6-DIMETHYL-PHENOXY)-ACETYLAMINO]-3-HYDROXY-5-PHENYL-PENTYL}-3-METHYL-2-(2-OXO-TETRAHYDRO-PYRIMIDIN-1-YL)-BUTYRAMIDE
NCGC00164576-01
NCGC00164576-02
RS-346
S1380_Selleck
UNII-2494G1JF75
|
|
6 |
|
Emtricitabine |
Approved, Investigational |
Phase 4 |
|
143491-57-0 |
60877 |
Synonyms:
(-)-(2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(−)-(2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(-)-(2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(-)-.beta.-L-FTC
(-)-2',3'-Dideoxy-5-fluoro-3'-thiacytidine
(−)-2'-deoxy-5-fluoro-3'-thiacytidine
(-)-2'-Deoxy-5-fluoro-3'-thiacytidine
(-)-b-2',3'-Dideoxy-5-fluoro-3'-thiacytidine
(-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine
(-)-beta-2',3'-Dideoxy-5-fluoro-3'-thiacytidine
(-)-cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one
(−)-cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one
(-)-cis-4-Amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one
(-)-Emtricitabine
(-)-FTC
(−)-FTC
(−)-β-2',3'-dideoxy-5-fluoro-3'-thiacytidine
(-)-Î’-2',3'-dideoxy-5-fluoro-3'-thiacytidine
(2R-cis)-4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone
(2R-cis)-4-Amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone
.beta.-L-(-)-(2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
1-(2-(Hydroxymethyl)oxathiolan-5-yl)-5-fluorocytosine
143491-54-7
143491-57-0
145213-48-5
2',3',5-FTC
2',3'-Dideoxy-5-fluoro-3'-thiacytidine
2'-Deoxy-5-fluoro-3'-oxa-4'-thiocytidine
2'-Deoxy-5-fluoro-3'-thiacytidine
2-FTC
3'-Thia-2'.3'-dideoxy-5-fluorocytidine
4-amino-5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one
4-Amino-5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one
4-Amino-5-fluoro-1-((2R,5S)-2-hydroxymethyl-[1,3]oxathiolan-5-yl)-1H-pyrimidin-2-one
4-Amino-5-fluoro-1-[(2R,5S)-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone
4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one
4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one
524W91
5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
5-Fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
5-Fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
|
5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)[1,3]oxathiolan-5-yl]cytosine
AC1L1U3I
AC1Q4KUB
beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine
BW 1592
BW 524W91
BW524W91
BW-524W91
C122114
C12599
C8H10FN3O3S
CHEBI:31536
CHEMBL885
CID60877
Coviracil
Coviracil(TM)
D01199
DB00879
dOTFC
DRG-0208
Emtricitabin
Emtricitabina
Emtricitabine
Emtricitabine (JAN/USAN/INN)
Emtricitabinum
Emtriva
Emtriva (TN)
Emtriva(TM)
FT-0080009
HMS2089I05
HSDB 7337
LS-135838
LS-173184
NCGC00164564-01
Racivir
RCV
SBB066061
TL8000958
UNII-G70B4ETF4S
ZINC03629271
|
|
7 |
|
Lamivudine |
Approved, Investigational |
Phase 4 |
|
134678-17-4 |
60825 |
Synonyms:
(-)-(2'R,5'S)-1-[2'-Hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine
(-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
(-)-1-[(2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(-)-2'-Deoxy-3'-thiacytidine
(-)-BCH 189
(-)-BCH-189
(-)-beta-L-2',3'-Dideoxy-3'-thiacytidine
(-)NGPB-21
(-)-SddC
(+/-) (Cis)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(+/-)-3TC
(+/-)-BCH-189
(+/-)-SddC
(2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one
.beta.-L-(-)-2',3'-dideoxy-3'-thiacytidine & Sho-Saiko-To
134678-17-4
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S)
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Galanthus Nivalis Agglutinin (GNA)
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Hippeastrum hybrid agglutinin( HHA)
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (+/-) (Cis)
2',3' Dideoxy 3' thiacytidine
2',3'-Dideoxy-3'-thiacytidine
3TC
3TC & GNA
3TC & SST
3TC (AIDS INITIATIVE) (AIDS INITIATIVE)
3TC and NV-01
3TC, Zeffix, Heptovir, Epivir, Epivir-HBV, Lamivudine
3'-Thia-2',3'-dideoxycytidine
480434-79-5
4-Amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone
4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one
4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one
AC-1416
AC1L1TZZ
AC1Q6C34
BCH 189
BCH189
BCH-189
BCH-790
beta-L-2',3'-Dideoxy-3'-thiacytidine
beta-L-3'-Thia-2',3'-dideoxycytidine
BIDD:GT0033
Bio-0652
b-L-2',3'-Dideoxy-3'-thiacytidine
b-L-3'-Thia-2',3'-dideoxycytidine
C07065
C8H11N3O3S
CCRIS 9274
CHEBI:133986
CHEMBL141
CID60825
CPD000466319
D00353
D019259
|
DB00709
DRG-0126
DTHC
Epivir
Epivir (TN)
Epivir(TM)
Epivir-HBV
Epzicom
FT-0082667
GG-714
GR 109714X
GR109714X
GR-109714X
Hepitec
Heptivir
Heptodin
Heptovir
HHA & 3TC
HHA & Lamivudine
HMS2051D21
HSDB 7155
L0217
Lamivir
Lamivudin
Lamivudina
lamivudine
Lamivudine
Lamivudine & GNA
Lamivudine (JAN/USP/INN)
Lamivudine [Usan:Ban:Inn]
Lamivudine [USAN:BAN:INN]
Lamivudine [USAN:INN:BAN]
Lamivudine, (2S-cis)-isomer
Lamivudine, (2S-cis)-Isomer
Lamivudinum
LMV
LS-2107
MLS000759424
MLS001424097
MolPort-002-507-347
NCGC00159341-03
NCGC00159341-04
NSC620753
S1706_Selleck
SAM001246582
SAM002589994
SMR000466319
STK801940
UNII-2T8Q726O95
Zeffix
Zefix
ZINC00012346
Î’-L-2',3'-dideoxy-3'-thiacytidine
Î’-L-3'-thia-2',3'-dideoxycytidine
|
|
8 |
|
Stavudine |
Approved, Investigational |
Phase 4 |
|
3056-17-5 |
18283 |
Synonyms:
1-(2,3-Dideoxy-b-D-glycero-pent-2-enofuranosyl)thymine
1-(2,3-Dideoxy-beta-D-glycero-2-pentenofuranosyl)thymine
1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine
1-(2,3-Dideoxy-β-D-glycero-pent-2-enofuranosyl)thymine
1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4(1H,3H)-dione
1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione
1-[5-(hydroxymethyl)-2,5-dihydro-2-furanyl]-5-methyl-2,4(1H,3H)-pyrimidinedione & Colony-stimulating factor 2
132425-31-1
2',3' Didehydro 3' deoxythymidine
2',3'-Anhydrothymidine
2',3'-Didehydro-2',3'-dideoxythmidine
2',3'-Didehydro-3'-deoxythimidine
2',3'-Didehydro-3'-deoxythymidine
2',3'-DIDEHYDRO-3'-DEOXYTHYMIDINE (DDI)
3'- Azido-3'-deoxythymidine & Granulocyte-macrophage colony-stimulating factor
3056-17-5
3'-Deoxy-2',3'-didehydrothymidine
3'-Deoxy-2'-thymidinene
AC1L2BQ9
AC1Q6BSH
AC-5263
BB_NC-1008
BIDD:GT0082
BMY 27857
BMY27857
BMY-27857
Bristol-myers brand OF stavudine
Bristol-Myers Brand of Stavudine
Bristol-myers squibb brand OF stavudine
Bristol-Myers Squibb Brand of Stavudine
BRN 0618327
C07312
CHEBI:207119
CHEMBL991
CID18283
CPD000058350
CPD000673569
D 1413
D 4T
D 4T (nucleoside)
D00445
D018119
D1413_SIGMA
D3580
d4T
D4T & GM-CSF
D4TMBY-27857-3
DB00649
ddeThd
ddeTyd
Dideoxydidehydrothymidine
Estavudina
|
Estavudina [INN-Spanish]
EU-0100336
FT-0082665
HMS2051O20
HSDB 7338
Lopac0_000336
LS-1160
MLS000028546
MLS000759504
MLS001055348
MLS001077292
MolPort-002-507-283
NCGC00023212-03
NCGC00023212-04
NCGC00023212-05
NCGC00023212-07
NCGC00023212-08
NCGC00023212-09
NCGC00023212-10
NSC 163661
NSC163661
SAM001246729
SAM002589948
sanilvudine
Sanilvudine
Sanilvudine (JAN)
SMR000058350
SMR000673569
Stavudin
stavudine
Stavudine
Stavudine (USAN/INN)
Stavudine [Usan:Ban:Inn]
Stavudine [USAN:BAN:INN]
Stavudine [USAN:INN:BAN]
Stavudine, monosodium salt
Stavudine, Monosodium Salt
Stavudinum
Stavudinum [INN-Latin]
STK801888
STV
Thymine, 1-(2,3-dideoxy-beta-D-glycero-pent-2-enofuranosyl)- (7CI,8CI)
UNII-BO9LE4QFZF
Zent
Zerit
Zerit (TN)
Zerit Xr
Zerit XR
Zerit(TM)
Zerut XR
ZINC00137884
|
|
9 |
|
Nevirapine |
Approved |
Phase 4 |
|
129618-40-2 |
4463 |
Synonyms:
11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one
11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & PRO 140 (Anti-CCR5 monoclonal antibody)
11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one
11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one
11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one
11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE
129618-40-2
1vrt
2hny
AC1L1I81
AC-643
BI RG 587
BIDD:GT0326
Bio-0789
BIRG 0587
BIRG 587
BIRG-0587
BIRG587
BIRG-587
BI-RG-587
BI-RG-587 & CD4-IgG
C07263
C15H14N4O
Cahill May Roberts Brand of Nevirapine
CHEBI:44659
CHEMBL57
CID4463
CPD000048458
D00435
D019829
DB00238
DB08311
Hemihydrate, nevirapine
HMS2051J09
HSDB 7164
|
I02-0310
LS-2289
MLS000084585
MLS000759409
MLS001055309
MLS001201730
MolPort-002-507-817
N11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e]-[1,4]diazepin-6-one & CD4-immunoadhesin
NCGC00065890-02
NEV
Nevirapina
nevirapine
Nevirapine
Nevirapine & CD4-IgG
Nevirapine & PRO 140
Nevirapine (JAN/USP/INN)
Nevirapine [USAN:INN]
Nevirapine anhydrous
Nevirapine hemihydrate
Nevirapine, anhydrous
NON-NUCLEOSIDE RT INHIBITOR NEVIRAPINE
NSC 641530
NSC641530
NVP
Promeco Brand of Nevirapine
S1742_Selleck
SAM001246551
SMR000048458
STK580320
UNII-99DK7FVK1H
Viramune
Viramune (TN)
Viramune(TM)
Viramune, BI-RG 587, Nevirapine
ZINC00004778
|
|
10 |
|
Tenofovir |
Experimental, Investigational |
Phase 4 |
|
147127-20-6 |
464205 |
Synonyms:
(R)-9-(2-Phosphonomethoxypropyl)adenine
(R)-9-(2-Phosphonylmethoxypropyl)adenine
(R)-PMPA
[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid
147127-20-6
206184-49-8
9-(2-Phosphonomethoxypropyl)adenine
9-(2-Phosphonylmethoxypropyl)adenine
9-(2-Phosphonylmethoxypropyl)adenine, (+-)-isomer
9-(2-Phosphonylmethoxypropyl)adenine, (R)-isomer - T357098
9-(2-Phosphonylmethoxypropyl)adenine, (S)-isomer
9-PMPA (tenofovir)
AC1LA9BO
AC-760
Anh. tenofovir
Anhydrous tenofovir
Apropovir
CHEBI:45809
CHEMBL483
CID464205
D,L-Tenofovir
DB00300
Disoproxil fumarate, tenofovir
Disoproxil, tenofovir
Fumarate, tenofovir disoproxil
GNA & Tenofovir
|
GS 1275
GS 1278
GS1278
HHA & Tenofovir
KS-5021
MolPort-003-850-411
NCGC00167535-01
Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- & Galanthus nivalis agglutinin (GNA)
Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- & Hippeastrum hybrid agglutinin( HHA)
Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- (9CI)
Phosphonic acid, [[2-(6-amino-9H-purin-9
PMPA
PMPA-(R)
S1401_Selleck
TDF
Tenefovir
Tenofovir
Tenofovir (anh.)
Tenofovir (anhydrous)
Tenofovir anhydrous
Tenofovir disoproxil
Tenofovir disoproxil fumarate
TFV
UNII-99YXE507IL
Viread
Viread, Tenofovir
|
|
11 |
|
Anti-Retroviral Agents |
|
Phase 4 |
|
|
|
12 |
|
HIV Protease Inhibitors |
|
Phase 4 |
|
|
|
13 |
|
protease inhibitors |
|
Phase 4 |
|
|
|
Synonyms:
|
14 |
|
Anti-HIV Agents |
|
Phase 4 |
|
|
|
15 |
|
Reverse Transcriptase Inhibitors |
|
Phase 4 |
|
|
|
16 |
|
Antimetabolites |
|
Phase 4 |
|
|
|
17 |
|
Liposomal doxorubicin |
|
Phase 4 |
|
|
31703 |
Synonyms:
|
LipoDox
liposomal doxorubicin
Pegylated Liposomal Doxorubicin Hydrochloride
|
|
18 |
|
Cytochrome P-450 CYP3A Inhibitors |
|
Phase 4 |
|
|
|
19 |
|
Cytochrome P-450 Enzyme Inhibitors |
|
Phase 4 |
|
|
|
20 |
|
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination |
|
Phase 4 |
|
|
|
21 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 3 |
|
33069-62-4 |
36314 |
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-epi-Paclitaxel
7-Epipaclitaxel
7-Epi-paclitaxel
7-epi-Taxol
7-Epitaxol
7-Epi-taxol
AB00513812
ABI 007
abi-007
ABI007
ABI-007
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
AC1L1IOG
AC1L1VJI
AC1L9AVF
AC-675
ACon1_002231
albumin-bound paclitaxel
Ambotz33069-62-4
ANX-513
Anzatax
Asotax
BIDD:PXR0046
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
Bris taxol
Bristaxol
BSPBio_000290
BSPBio_001152
BSPBio_002614
C07394
C466458
C47H51NO14
Capxol
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
cMAP_000068
CPD-8718
D00491
DB01229
DHP-107
DHP-208
DivK1c_000441
DRG-0190
DTS-301
Ebetaxel
EmPAC
Epitaxol
EU-0101201
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
|
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LipoPac
LMPR0104390001
Lopac0_001201
LS-31070
MBT 0206
MEGxp0_001940
Micellar Paclitaxel
Mitotax
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
MPI-5018
nab-paclitaxel
Nanotaxel
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
NCI60_000601
Neuro_000060
NINDS_000441
NK 105
Nova-12005
NP-010981
NSC 125973
NSC125973
NSC-125973
NSC358882
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
paclitaxel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S1150_Selleck
S-8184 Paclitaxel Injectable Emulsion
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
Spectrum_001536
SPECTRUM1503908
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
ST50306996
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TaxAlbin
Taxol
TAXOL
TAXOL (TN)
Taxol a
Taxol A
Taxol Konzentrat
TAXOL, 10-EPI,
Taxol, bris
Taxol.RTM. (Registered Trademark)
TXL
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
weekly paclitaxel
Xorane
Yewtaxan
|
|
22 |
|
Zidovudine |
Approved |
Phase 2, Phase 3 |
|
30516-87-1 |
35370 |
Synonyms:
1-(3-Azido-2,3-dideoxy-beta-D-ribofuranosyl)thymine
3' Azido 2',3' dideoxythymidine
3' Azido 2',3' Dideoxythymidine
3' Azido 3' deoxythymidine
3&prime
30516-87-1
399024-19-2
3'-Azido-2',3'-dideoxythymidine
3'-Azido-2',3'-Dideoxythymidine
3'-Azido-3'-deoxythymidine
3-Azido-3-deoxythymidine
3'-Azido-3'-deoxythymidine & Concanavalin A
3'-Azido-3'-deoxythymidine & Erythropoietin
3'-Azido-3'-deoxythymidine & Heteropolyoxotungstate PM-19
3'-Azido-3'deoxythymidine & Interferon .alpha.
3'-Azido-3'-deoxythymidine & Interleukin-1
3'-Azido-3'-deoxythymidine & Interleukin-2
3'-Azido-3'-deoxythymidine & Interleukin-6
3'-Azido-3'-deoxythymidine & Lithium & Erythropoietin
3'-Azido-3'-deoxythymidine & Lithium & Interleukin-1
3'-Azido-3'-deoxythymidine & Lithium & Interleukin-6
3'-Azido-3'-deoxythymidine & Lymphoblastoid Interferon
3'-Azido-3'-deoxythymidine & Sho-Saiko-To
3'-Azido-3'-deoxythymidine (AIDS)
3'-azido-3'-deoxythymidine, AZT
3'-Azidothymidine
3'-Deoxy-3'-azidothymidine
A2169_SIGMA
AC1L1TKL
AC1Q2OEK
antiviral
Antiviral azt
Antiviral AZT
Apo-Zidovudine
-Azido-3&prime
azidodeoxythymidine
Azidothymidine
AZT
AZT & CD4(178)-PE 40
AZT & Colony-stimulating factor 2
AZT & Concanavalin A (ConA)
AZT & EPO
AZT & GM-CSF
AZT & HPA
AZT & IFN.alpha.
AZT & IL-1
AZT & IL-2
AZT & IL-6
AZT & Interferon-.alpha.-2
AZT & Li & EPO
AZT & Li & GM-CSF
AZT & Li & IL-1
AZT & Li & IL-6
AZT & Lymphoblastoid Interferon
AZT & NP (from PHCA or HSA)
AZT & PM-19
AZT & rIFN.alpha.2
AZT & rsCD4 & rIFN.alpha.A
AZT & rsT4
AZT & sCD4
AZT & srCD4
AZT & SST
AZT (antiviral)
AZT (Antiviral)
AZT antiviral
AZT Antiviral
AZT TRANSPLACENTAL CARCINOGENESIS STUDY
AZT, antiviral
AZT, Antiviral
AZT+PRO 140
Aztec
BB_NC-1012
BPBio1_000403
BRD-K72903603-001-04-6
BSPBio_000365
BSPBio_003153
BW a509U
BW A509U
BWA 509u
BWA 509U
BW-A 509U
BWA509u
BWA-509u
BWA509U
BWA-509U
BW-A509U
BW-A-509U
C07210
CCRIS 105
|
CHEBI:10110
CHEBI:127307
CHEMBL129
CID35370
Compound S
Cpd S
CPD000058351
D00413
D015215
DB00495
-deoxythymidine
DivK1c_000524
DRG-0004
DS-4152 & AZT
HMS1921J20
HMS2090G11
HMS2092D06
HMS501K06
HSDB 6515
IDI1_000524
Interferon AD + 3'-azido-3'-deoxythymidine
Intron A & AZT
K7 [P Ti2 W10 O40]
KBio1_000524
KBio2_001828
KBio2_004396
KBio2_006964
KBio3_002653
KBioGR_000703
KBioSS_001828
Liposomal AZT-SN-1
Liposomal AZT-SN-3
LS-1159
Met-SDF-1.beta. & AZT
Met-SDF-1.beta. & Zidovudine
MLS000028548
MLS001055351
MLS001076358
MLS002153202
MLS002222249
MolPort-002-507-286
NCGC00023945-03
NCGC00023945-04
NCGC00023945-05
NCGC00023945-08
NCGC00178237-01
NCGC00178237-02
NINDS_000524
Novo-Azt
NSC 602670
PC-SOD+AZT
Prestwick3_000333
Propolis+AZT
Racemic Liposomal AZT
racemic-dipalmitoylglycerophospho-AZT (in a lipid vesicle)
Retrovir
Retrovir (TN)
Retrovir(TM)
rIFN-beta seron & AZT
SAM002548971
SMR000058351
SN-1-dipalmitoylglycerophospho-AZT (in a lipid vesicle)
SN-3-dipalmitoylglycerophospho-AZT (in a lipid vesicle)
SPBio_000834
Spectrum_001348
SPECTRUM1502109
Spectrum2_000927
Spectrum3_001507
Spectrum4_000332
Spectrum5_001101
STK801891
UNII-4B9XT59T7S
ZDV
zidovudin
Zidovudin
Zidovudina
Zidovudina [Spanish]
zidovudine
Zidovudine
Zidovudine (JAN/USP/INN)
ZIDOVUDINE [AZT]
Zidovudine [USAN:INN:BAN:JAN]
Zidovudine EP III
Zidovudine+PRO 140
Zidovudinum
Zidovudinum [Latin]
ZINC03779042
ZVD
|
|
23 |
|
Ritonavir |
Approved, Investigational |
Phase 2, Phase 3 |
|
155213-67-5 |
392622 |
Synonyms:
1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
155213-67-5
1hxw
1sh9
538, ABT
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
A-84538
Abbott 84538
ABBOTT-84538
ABT 538
ABT 84538
ABT538
ABT-538
AC1L94GB
AC-733
AKOS000280930
BIDD:GT0387
BIDD:PXR0023
Bio-0093
C07240
C37H48N6O5S2
CHEBI:45409
CHEMBL163
CID392622
CPD000466395
D00427
D019438
DB00503
|
DRG-0244
FT-0082824
HMS2051B08
HSDB 7160
LS-148860
MLS000759541
MLS001424063
MolPort-000-883-877
N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide
NCGC00159462-02
Norvir
Norvir (TM)
Norvir (TN)
Norvir Sec
NSC693184
RIT
ritonavir
Ritonavir
Ritonavir (JAN/USAN/INN)
Ritonavir [USAN]
Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS.
Ritonavirum
RTV
S1185_Selleck
SAM001246783
SMR000466395
STK634209
ZINC03944422
|
|
24 |
|
Abacavir |
Approved, Investigational |
Phase 2, Phase 3 |
|
136470-78-5 |
65140 441300 |
Synonyms:
(+/-)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol
(+/-)-Abacavir
(1S,4R)-4-(2-Amino-6-(cyclopropylamino)-9H-purin-9-yl)-2-cyclopentene-1-methanol
(1S,4R)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol
[(1S,4R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol
{(1S-cis)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol
136470-78-5
1592U89
168146-84-7
abacavir
Abacavir
Abacavir (INN)
Abacavir [INN]
Abacavir succinate
Abacavir sulfate
ABC
|
AC1L9AXG
Bio-0001
C07624
CHEBI:421707
CHEMBL1380
CID441300
D07057
DB01048
Epzicom
NCGC00164560-01
NCGC00164560-02
NSC742406
Trizivir
Ziagen
Ziagen (TM)(*Succinate salt*)
ZINC02015928
|
|
25 |
|
Albumin-Bound Paclitaxel |
|
Phase 3 |
|
|
|
26 |
|
Antimitotic Agents |
|
Phase 3 |
|
|
|
27 |
|
Tubulin Modulators |
|
Phase 3 |
|
|
|
28 |
|
Antibiotics, Antitubercular |
|
Phase 3 |
|
|
|
29 |
|
Anti-Bacterial Agents |
|
Phase 3 |
|
|
|
30 |
|
Dideoxynucleosides |
|
Phase 2, Phase 3 |
|
|
|
31 |
|
Etoposide |
Approved |
Phase 2 |
|
33419-42-0 |
36462 |
Synonyms:
(−)-etoposide
(-)-Etoposide
121471-01-0
136598-18-0
201594-04-9
33419-42-0
35317-32-9
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-b-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-β-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4-Demethylepipodophyllotoxin b-D-ethylideneglucoside
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4-demethylepipodophyllotoxin β-D-ethylideneglucoside
4-Demethylepipodophyllotoxin β-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
51854-34-3
76576-58-4
9-((4,6-O-Ethylidine-b-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
9-((4,6-O-Ethylidine-β-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
AB00438905
AC1L1FN8
AC1L1VT3
AC1L6246
AC1NR4OG
AC1O4WGG
AC1O7M1N
AC1Q47JJ
alpha-D-Glucopyranosyl isomer etoposide
Ambap33419-42-0
Baxter brand OF etoposide
Baxter oncology brand OF etoposide
Bio1_000489
Bio1_000978
Bio1_001467
BPBio1_000673
BRD-K37798499-001-02-5
Bristol myers brand OF etoposide
Bristol myers squibb brand OF etoposide
Bristol-myers brand OF etoposide
Bristol-myers squibb brand OF etoposide
BSPBio_000611
C01576
CCRIS 2392
Celltop
CHEBI:4911
CHEBI:588795
CHEMBL44657
CID11758093
CID284997
CID3310
CID36462
CID5284558
CID6419930
CID6610299
CPD000112002
D00125
DB00773
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl epipodophyllotoxin ethylidine glucoside
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
E0675
E1383_SIGMA
EINECS 251-509-1
Epipodophyllotoxin VP-16213
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Eposide
Eposin
Eposin, Vepesid, VP-16, Toposar, Etoposide
Eto gry
Eto-gry
Etomedac
ETOP
Etopol
Etopophos
Etopophos (phosphate salt)
Etopos
etoposide
|
Etoposide
Etoposide (JP15/USP/INN)
Etoposide (VP16)
Etoposide [USAN:INN:BAN:JAN]
Etoposide pierre fabre
Etoposide teva
Etoposide, (5a alpha)-isomer
Etoposide, (5a alpha,9 alpha)-isomer
Etoposide, (5S)-isomer
Etoposide, alpha D glucopyranosyl isomer
Etoposide, alpha-D-glucopyranosyl isomer
Etoposido
Etoposido [INN-Spanish]
Etoposido ferrer farma
Etoposidum
Etoposidum [INN-Latin]
Etosid
Exitop
Ferrer brand OF etoposide
Gry brand OF etoposide
HMS1569O13
HMS2052N05
HMS2089F14
HSDB 6517
I06-0248
KBioSS_002410
Lastet
Lemery brand OF etoposide
LS-1214
Medac brand OF etoposide
MLS000049957
MLS001074951
MLS001424283
MLS002153463
MLS002207239
MLS002222184
MolPort-003-983-431
MolPort-004-905-001
MolPort-004-955-161
NCGC00025056-02
NChemBio.2007.10-comp19
nchembio.573-comp8
nchembio873-comp2
NK 171
Novartis brand OF etoposide
NSC 141540
NSC141540
NSC-141540
Onkoposid
Onkoworks brand OF etoposide
Pharmachemie brand OF etoposide
Pierre fabre brand OF etoposide
Prasfarma brand OF etoposide
Prestwick_211
Prestwick0_000396
Prestwick1_000396
Prestwick2_000396
Prestwick3_000396
Riboposid
Ribosepharm brand OF etoposide
S1225_Selleck
SAM001246880
Sanfer brand OF etoposide
SMR000112002
SPBio_002532
ST056353
Tedec meiji brand OF etoposide
Teva brand OF etoposide
Teva, etoposide
Toposar
trans-Etoposide
UNII-6PLQ3CP4P3
Vepesid
VePesid
VePESID (TN)
Vepesid J
Vepeside
Vépéside sandoz
Vépéside-sandoz
VP 16
VP 16 (pharmaceutical)
VP 16213
VP 16-213
VP-16
VP-16-213
ZINC03830818
ZINC03938684
Zuyeyidal
|
|
32 |
|
Nicotine |
Approved |
Phase 2 |
|
54-11-5 |
942 89594 |
Synonyms:
(−
(-)-3-(1-Methyl-2-pyrrolidyl)pyridine
(-)-3-(N-Methylpyrrolidino)pyridine
(−)-nicotine
(-)-Nicotine
(-)-Nicotine solution
(+)-Nicotine
(2S) 3-(1-Methyl-pyrrolidin-2-yl)-pyridine
(R)-3-(1-Methyl-2-pyrrolidinyl)pyridine
(R,S)-Nicotine
(S)-(−)-nicotine
(S)-(-)-Nicotine
(S)-(-)-NICOTINE, 3-[(2S)-1-METHYL-2-PYRROLIDINYL] PYRIDINE
(S)-3-(1-methylpyrrolidin-2-yl)pyridine
(S)-3-(1-Methylpyrrolidin-2-yl)pyridine
(S)-3-(N-methylpyrrolidin-2-yl)pyridine
(S)-3-(N-Methylpyrrolidin-2-yl)pyridine
(S)-Nicotine
)-1-Methyl-2-(3-pyridyl)pyrrolidine
)-Nicotine
)-Nicotine solution
1-Methyl-2-(3-pyridal)-pyrrolidene
1-Methyl-2-(3-pyridal)-pyrrolidine
1-Methyl-2-(3-pyridiyl)pyrrolidine
1-Methyl-2-(3-pyridyl)pyrrolidine
1uw6
2'-beta-H-Nicotine
3-(1-Methyl-2-pyrollidinyl)pyridine
3-(1-Methyl-2-pyrrolidinyl)pyridine
3-(1-Methyl-2-pyrrolidinyl)-pyridine
3-(1-Methylpyrrolidin-2-yl)pyridine
3-(2-(N-methylpyrrolidinyl))pyridine
3-(2-(N-Methylpyrrolidinyl))pyridine
3-(N-methylpyrollidino)pyridine
3-(N-Methylpyrollidino)pyridine
3-(N-Methylpyrrolidino)pyridine
3-[(2S)-1-methylpyrrolidin-2-yl]pyridine
36733_FLUKA
36733_RIEDEL
3-N-Methylpyrrolidine
434F7990-3240-4A43-ACEC-E6CC1E495FA0
46343_FLUKA
46343_RIEDEL
54-11-5
a -N-Methylpyrrolidine
AC1L3I79
AC1Q3ZOC
AI3-03424
alpha-N-Methylpyrrolidine
a-N-Methylpyrrolidine
BB_NC-0777
beta-Pyridyl-alpha-N-methyl pyrrolidine
beta-Pyridyl-alpha-N-methylpyrrolidine
BIDD:GT0599
Bitartrate, nicotine
Black Leaf
Black Leaf 40
bmse000105
BRD-K05395900-322-02-1
C00745
Campbell's Nico-Soap
Caswell No. 597
CCRIS 1637
CHEBI:17688
CHEMBL3
CID89594
Commit
CPD000059074
D03365
delta-Nicotine
Destruxol
Destruxol Orchid Spray
DL-Tetrahydronicotyrine
D-Nicotine
EINECS 200-193-3
Emo-Nik
ENT 3,424
EPA Pesticide Chemical Code 056702
Flux Maag
Fumeto bac
Fumetobac
Habitrol
|
Habitrol (TN)
HSDB 1107
L(-)-nicotine
L(−)-nicotine
L(-)-Nicotine
L-3-(1-Methyl-2-pyrrolidyl)pyridine
L-Nicotine
LS-202
Mach-Nic
Methyl-2-pyrrolidinyl)pyridine
Micotine
MLS001055457
MLS001335905
MolPort-000-744-731
N3876_SIGMA
N5511_FLUKA
N5511_SIGMA
NCGC00090693-01
NCGC00090693-02
NCGC00090693-03
NCGC00090693-04
NCGC00090693-05
NCGC00090693-06
NCGC00090693-07
NCT
Niagara P.A. Dust
Nicocide
Nicoderm
Nicoderm Cq
Nicoderm Patch
Nico-Dust
Nico-Fume
Nicorette
Nicorette Plus
Nicotin
Nicotina
Nicotina [Italian]
nicotine
Nicotine
Nicotine (compounds related to)
Nicotine (USP)
Nicotine [BSI:ISO]
Nicotine [UN1654] [Poison]
Nicotine [USAN]
Nicotine Alkaloid
NICOTINE AND SALTS
Nicotine betadex
Nicotine bitartrate
Nicotine Patch
Nicotine polacrilex
Nicotine Polacrilex
nicotine replacement patch
Nicotine tartrate
Nicotrol
Nicotrol Inhaler
Nicotrol Ns
Nic-Sal
Nictoine patch
Nikotin
Nikotin [German]
Nikotyna
Nikotyna [Polish]
NSC 5065
NSC97238
Ortho N-4 Dust
Ortho N-5 Dust
PDSP1_000113
PDSP1_000465
PDSP2_000463
PDSP2_000555
Prostep
R)-(+)-Nicotine
RCRA waste no. P075
RCRA waste number P075
SAM002564224
SDCCGMLS-0066911.P001
SMR000059074
Tartrate, nicotine
Tendust
Transdermal Nicotine
UN1654
|
|
33 |
|
Lenalidomide |
Approved |
Phase 1, Phase 2 |
|
191732-72-6 |
216326 |
Synonyms:
191732-72-6
1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
1-oxo-2-(2,6-Dioxopiperidin-3-yl)-4-aminoisoindoline
3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione
3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione
3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione
3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione
346670-73-3
443912-14-9
AC1L50II
AC-914
AKOS005146276
ALBB-015321
Bio-0168
C467567
CC 5013
CC5013
CC-5013
CC-5013, Revlimid, Lenalidomide
CDC 501
CDC-501
CDC-5013
Celgene brand of lenalidomide
Celgene brand OF lenalidomide
CHEMBL848
CID216326
D04687
|
DB00480
EC-000.2340
ENMD-0997
I06-0831
IMID-1
IMiD3
IMiD3 cpd
IMiD3 CPD
IMID-5013
Lenalidomida
lenalidomide
Lenalidomide
Lenalidomide (USAN/INN)
Lenalidomide [USAN]
LS-184040
MolPort-003-848-370
NCGC00167491-01
NSC747972
Revamid
Revimid
Revlimid
Revlimid (Celgene)
Revlimid (TN)
S1029_Selleck
STK639603
Thalidomide analog CC-5013
UNII-F0P408N6V4
|
|
34 |
|
Indinavir |
Approved |
Phase 2 |
|
150378-17-9 |
5362440 |
Synonyms:
(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-pentonamide
(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-Pentonamide
(2S)-1-[(2S,4S)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
150378-17-9
157810-81-6
157810-81-6 (sulfate (1:1) (salt))
166746-42-5
1c6y
1hsg
1hsh
1k6c
1sdt
1sdu
1sdv
1sgu
216884-06-9
2avo
2avs
2avv
2bpx
AC1L1U7I
AC-20034
AKOS000280989
BIDD:GT0378
BIDD:PXR0141
C07051
C36H47N5O4
CHEBI:44032
Compound J
|
Crixivan
Crixivan (TM)
DB00224
IDV
indinavir
Indinavir
Indinavir (*1:1 Sulfate salt*)
Indinavir [USAN]
Indinavir anhydrous
Indinavir sulfate
Indinavir sulphate
Indinavir, sulfate (1:1)
Indinavir, Sulfate (1:1)
L 735524
L-735 524
L-735,524
L-735524
LS-173382
MK-639
MolPort-000-883-804
N-[2(R)-HYDROXY-1(S)-INDANYL]-5-[(2(S)-TERTIARY BUTYLAMINOCARBONYL)-4(3-PYRIDYLMETHYL)PIPERAZINO]-4(S)-HYDROXY-2(R)-PHENYLMETHYLPENTANAMIDE
NCGC00159460-02
NSC697197
Propolis & 4-Hydroxy-N-(2-hydroxy-2,3-dihydro-1H-1-indanyl)-N'-(1,1-dimethylethyl)-2-phenylmethyl-5-[4-(3-pyridylmethyl)-1-piperzinyl]hexanediamide
Propolis+Indinavir
RS-253
Sulfate, indinavir
UNII-9MG78X43ZT
|
|
35 |
|
Bevacizumab |
Approved, Investigational |
Phase 2 |
|
216974-75-3 |
|
Synonyms:
216974-75-3
antiVEGF
Anti-VEGF Humanized Monoclonal Antibody
anti-VEGF monoclonal antibody
Anti-VEGF monoclonal antibody
Avastin
Avastin (TN)
bevacizumab
|
Bevacizumab
Bevacizumab (genetical recombination)
Bevacizumab (genetical recombination) (JAN)
bevacizumab-awwb
D06409
R-435
rhuMAb-VEGF
|
|
36 |
|
Vinblastine |
Approved |
Phase 2 |
|
865-21-4 |
13342 241903 |
Synonyms:
(2a,2'b,3b,4a,5b)-VINCALEUKOBLASTINE
(2ALPHA,2'BETA,3BETA,4ALPHA,5BETA)-VINCALEUKOBLASTINE
(2xi,3beta,4'beta,19xi)-vincaleukoblastine
(2Α,2'β,3β,4α,5β)-vincaleukoblastine
(3aR-(3aalpha,4beta,5beta,5abeta,9(3R*,5S*,7R*,9S*),10bR*,13aalpha))-methyl 4-(acetyloxy)-3a-ethyl-9-(5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-9-(methoxycarbonyl)-2H-3,7-methanoazacycloundecino(5,4-b)indol-9-yl)-3a,4,5,5a,6,11,12,13a-octahydro-5-hydroxy-8-methoxy-6-methyl-1H-indolizino(8,1-cd)carbazole-5-carboxylate
143-67-9
1z2b
29060-LE
865-21-4
AC1L21JC
AC1L68D2
AC1MXZJ2
AC-20335
BIDD:PXR0201
Bio-0111
BRD-K01188359-065-02-5
BSPBio_001228
BSPBio_003594
C07201
C46H58N4O9
CCRIS 9002
Cell pharm brand OF vinblastine sulfate
Cellblastin
CHEBI:171516
CHEBI:27375
CHEMBL159
CHEMBL607706
CID13342
CID241903
CID3823887
CID6710780
D08675
DB00570
EG labo brand OF vinblastine sulfate
EINECS 212-734-0
Faulding brand OF vinblastine sulfate
Gastrozepin brand OF vinblastine sulfate
Gry brand OF vinblastine sulfate
Hexal brand OF vinblastine sulfate
HMS2090K05
HSDB 3263
KBio3_003033
Lemblastine
Lemery brand OF vinblastine sulfate
Lilly brand OF vinblastine sulfate
|
LS-1859
LS-187263
MolPort-002-518-262
MolPort-005-910-359
NCGC00022585-04
NCGC00181127-01
NChemBio.2007.10-comp22
nchembio873-comp22
NCI60_004200
NCI-C04842
NDC 0002-1452-01
Neuro_000020
Nincaluicolflastine
NSC 47842
Rozevin
SPBio_000680
Spectrum2_000890
Spectrum3_001994
STOCK1N-38480
Sulfate, vinblastine
UNII-5V9KLZ54CY
Velban
Velbe
Vinblastin
Vinblastin hexal
Vinblastina
Vinblastina (TN)
Vinblastina [Dcit]
Vinblastina [DCIT]
Vinblastina lilly
vinblastine
Vinblastine
Vinblastine (INN)
Vinblastine [INN:BAN]
Vinblastine sulfate
Vinblastine Sulfate
Vinblastinsulfat-gry
Vinblastinum
Vinblastinum [INN-Latin]
Vincaleucoblastin
Vincaleucoblastine
Vincaleukoblastine
Vincoblastine
VLB
VR-8
|
|
37 |
|
Saquinavir |
Approved, Investigational |
Phase 2 |
|
127779-20-8 |
60787 |
Synonyms:
(2s)-N-[(2s,3r)-4-[(2s,3s,4as,8as)-3-(Tert-Butylcarbamoyl)-3,4,4a,5,6,7,8,8a-Octahydro-1h-Isoquinolin-2-Yl]-3-Hydroxy-1-Phenyl-Butan-2-Yl]-2-(Quinolin-2-Ylcarbonylamino)butanediamide
(2S)-N-[(2S,3R)-4-[(3S)-3-(Tert-butyl-C-hydroxycarbonimidoyl)-decahydroisoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-[(quinolin-2-yl)formamido]butanediimidate
(2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinoline-2-carbonylamino)butanediamide
127779-20-8
1hxb
2fgu
2fgv
AB00514056
AC-16711
AC1L9ATC
AKOS000280831
Ambap127779-20-8
BIDD:GT0323
BIDD:PXR0010
BPBio1_001373
BRD-K09963420-066-03-4
BSPBio_001248
CHEBI:45279
CHEMBL114
CID441243
CIS-N-TERT-BUTYL-DECAHYDRO-2-[2(R)-HYDROXY-4-PHENYL-3(S)-[[N-2-QUINOLYLCARBONYL-L-ASPARAGINYL]AMINO]BUTYL]-(4AS)-ISOQUINOLINE-3(S)-CARBOXAMIDE
D00429
Fortovase
Fortovase (TN)
Fortovase(TM)
Invirase
Invirase(TM)(monomesylate)
|
LS-187081
MLS001195635
MLS001304735
MolPort-000-883-824
Monomethanesulfonate, saquinavir
NCGC00091469-02
NSC722663
Prestwick0_001114
Prestwick1_001114
Prestwick2_001114
Prestwick3_001114
QNC-ASN-HPH-DIQ-NTB
Ro 318959
Ro 31-8959
Ro-31-8959
ROC
saguinavir
Saquinavir
SAQUINAVIR
Saquinavir (JAN/USP/INN)
Saquinavir mesylate
Saquinavir monomethanesulfonate
Saquinivir
Sequinavir
SMR000469157
SPBio_003114
SQV
|
|
38 |
|
Mitoxantrone |
Approved, Investigational |
Phase 2 |
|
65271-80-9 |
4212 |
Synonyms:
1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
1,4-DIHYDROXY-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-anthracenedione
1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONE
1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthra-9,10-quinone
1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracene-9,10-dione
1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione
1,4-Dihydroxy-5,8-bis(5-hydroxy-3-azapentylamino)anthrachinon
1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione
1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione
137635-96-2
2fum
5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone
65271-80-9
70476-82-3
70476-82-3 (hydrochloride)
70711-41-0
70711-41-0 (acetate)
70945-62-9
9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)- (9CI)
AB00053716
AC1L1HNY
Acetate, mitoxantrone
AHP brand OF mitoxantrone hydrochloride
Amgen brand OF mitoxantrone hydrochloride
AN-584/42007670
ASTA medica brand OF mitoxantrone hydrochloride
Baxter oncology brand OF mitoxantrone hydrochloride
BIDD:PXR0181
BPBio1_000627
BRD-K21680192-300-05-2
BRD-K21680192-300-07-8
BRN 2795126
BSPBio_000569
BSPBio_003160
C11195
C22H28N4O6
CAS-70476-82-3
CCRIS 7604
CHEBI:50729
CHEMBL58
CID4212
Columbia brand OF mitoxantrone hydrochloride
D08224
DB01204
DHAD
DHAQ
DHAQ (*Diacetate salt*)
DHAQ HCl
Dihydroxyanthraquinone
DivK1c_000516
HMS2090D05
Hydrochloride, mitoxantrone
IDI1_000516
Inibsa brand OF mitoxantrone hydrochloride
KBio1_000516
KBio2_002135
KBio2_004703
KBio2_007271
KBio3_002660
KBioGR_001531
KBioSS_002135
Lederle brand OF mitoxantrone hydrochloride
Liposome Encapsulated Mitoxantrone (LEM)
Lopac0_000779
Lopac-M-6545
LS-20638
Misostol
Misostol (TN)
Mitox
|
Mitoxanthrone
Mitoxantron
Mitoxantrona
Mitoxantrona [INN-Spanish]
mitoxantrone
Mitoxantrone
Mitoxantrone (free base)
Mitoxantrone (INN)
Mitoxantrone [INN]
Mitoxantrone 2HCl
Mitoxantrone acetate
Mitoxantrone dihydrochloride
Mitoxantrone HCl
Mitoxantrone hydrochloride
MITOXANTRONE, 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)ANTHRA-9,10-QUINONE
MITOXANTRONE, Mitoxantrone Hydrochloride, Mitoxantrone dihydrochloride, MITOXANTHRONE HYDROCHLORIDE
Mitoxantronum
Mitoxantronum [INN-Latin]
Mitozantrone
Mitozantrone hydrochloride
Mitroxone
MIX
MLS002703044
MolPort-003-849-239
NCGC00015693-01
NCGC00015693-02
NCGC00015693-04
NCGC00162251-01
NChemBio.2007.10-comp17
NCI60_002276
NCI60_002535
Neuro_000153
NINDS_000516
Novantron
Novantrone
Novantrone(R) (mitoxantrone for injection concentrate)
NSC 279836
NSC279836
NSC-279836
NSC-287836
NSC299195
NSC-299195
NSC301739
NSC-301739
NSC-301739D
Onkotrone
Pralifan
Prestwick0_000385
Prestwick1_000385
Prestwick2_000385
Prestwick3_000385
Ralenova
S2485_Selleck
SMP2_000179
SMR001549953
SPBio_000756
SPBio_002490
Spectrum_001655
Spectrum2_000908
Spectrum3_001590
Spectrum4_000866
Spectrum5_001205
SR-01000076001
SR-01000076001-7
STK631833
UNII-BZ114NVM5P
VU0244399-2
Wyeth brand OF mitoxantrone hydrochloride
|
|
39 |
|
Alitretinoin |
Approved, Investigational |
Phase 2 |
|
5300-03-8 |
444795 449171 |
Synonyms:
(2E,4E,6Z,8E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoate
(2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
(2E,4E,6Z,8E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
(7E,9Z,11E,13E)-Retinoate
(7E,9Z,11E,13E)-retinoic acid
(7E,9Z,11E,13E)-Retinoic acid
(9cis)-retinoic acid
.beta.-Retinoic acid
[3H]Retinoic acid
15-Apo-beta-caroten-15-Oate
15-Apo-beta-caroten-15-Oic acid
187175-63-9
1n4h
302-79-4
5300-03-8
56573-65-0
7005-78-9
9 cis Retinoic acid
9 Cis Retinoic Acid
9(Z)-Retinoate
9(Z)-Retinoic acid
9-cis RA
9-cis Retinoic Acid
9-cis-RA
9-cis-Retinoate
9-cis-retinoic acid
9-CIS-RETINOIC ACID
9-cis-Tretinoin
9CRA
9C-RA
9-CRA
9CRA compound
9-Retinoate
9-Retinoic acid
A-Acido (Argentina)
Aberel
Aberela
Aberela [Norway]
AC1L9GWO
AC1L9MT9
AC1Q1J2J
AC-6824
Accutane Roche
Acid, Retinoic
Acid, trans-Retinoic
Acid, Vitamin A
Acnavit
Acnavit [Denmark]
AGN 100335
AGN 192013
AGN-192013
Airol
Aknefug
Aknoten
AKOS000280845
Alitretinoin
Alitretinoin (USAN)
Alitretinoin [USAN]
alitretinoina
Alitretinoina
Alitretinoína
alitretinoine
Alitretinoine
Alitrétinoïne
alitretinoinum
Alitretinoinum
all-trans- Vitamin a1 acid
all-trans-beta-Retinoate
all-trans-beta-Retinoic acid
all-trans-b-Retinoate
all-trans-b-Retinoic acid
all-trans-Tretinoin
all-trans-Vitamin a acid
alpha-Vitaminsyre
ALRT 1057
ALRT-1057
ATRA
AT-RA
Atragen
Atra-IV
Atralin
Avita
Avita (TN)
Avita Gel
A-Vitaminsyre
Avitoin
Avitoin [Norway]
BAL4079
BAL-4079
BB_NC-1005
beta-Ra
beta-Retinoate
beta-Retinoic acid
Betarretin
BIDD:GT0483
BIDD:PXR0081
BML2-E05
BML2-E06
bmse000562
BPBio1_000082
b-Retinoate
b-Retinoic acid
BRN 2057223
BSPBio_000074
BSPBio_001495
BSPBio_001500
C00777
C15493
CCRIS 3294
CCRIS 7098
CHEBI:15367
CHEBI:50648
CHEMBL38
CHEMBL705
CID444795
CID449171
Cordes vas
Cordes VAS [Germany]
CPD000058245
D00094
D014212
D02815
DB00523
DB00755
DB00982
Dermairol
Effederm
Effederm [France]
EINECS 206-129-0
Epi-aberel
EU-0101061
Eudyna
HMS1361K17
HMS1361K22
HMS1568D16
HMS1791K17
HMS1791K22
HMS1921D14
|
HMS1989K17
HMS1989K22
HMS2089D20
HMS2092N11
HMS502N05
HSDB 2169
HSDB 7186
I04-0008
I14-2351
IDI1_000903
IDI1_033965
IDI1_033970
Isotretinoin retinoate
Isotretinoin retinoic acid
L000833
LG-100057
LGD 100057
LGD 1057
LGD-1057
LMPR01090019
LMPR01090022
Lopac0_001061
LS-1154
LS-1328
Lsotretinoin
MLS000028588
MLS001076515
MLS002207234
MLS002222211
MolPort-000-883-857
MolPort-002-507-281
NCGC00017280-06
NCGC00017280-17
NCGC00021808-04
NCGC00021808-05
NCGC00021808-06
NCGC00021808-07
NCGC00021808-09
NCGC00021808-14
NCGC00021808-15
NCGC00161590-01
NCGC00161590-02
NCGC00161590-03
NCGC00161590-04
NCGC00161590-05
NCGC00161590-06
NCGC00161590-07
nchembio.106-comp3
nchembio.154-comp2
nchembio861-comp8
Nexret
NSC 122758
NSC 659772
NSC122758
NSC-122758
NSC659772
NSC-659772
Panretin
Panretin (TN)
Panretin gel
Panretin Gel
Panretyn
Panrexin
PDT-002-002
Prestwick_424
Prestwick2_000257
Prestwick3_000257
R 2625
R0064
R2625_SIGMA
R4643_SIGMA
REA
Renova
Renova (TN)
Retacnyl
Retin a
Retin A
Retin A (TN)
Retin-a
Retin-A
Retin-a micro
Retin-A Micro
Retinoate
Retinoic acid
Retinova
Retionic acid
Retisol-A
Ro 1-5488
Ro-04-4079
S1653_Selleck
Salt, Tretinoin Zinc
SAM002264647
SMR000058245
Solage
SPECTRUM1502016
Spectrum5_001746
Spectrum5_001933
Spectrum5_001935
SR-01000000239
SR-01000000239-14
SR-05000013784
SR-05000013784-1
ST057075
Stieva-A
Stieva-a Forte
STK801887
STOCK1N-38565
Toctino
trans Retinoic Acid
trans-Retinoate
trans-Retinoic acid
trans-Vitamin a acid
Tretin M
tretinoin
Tretinoin
Tretinoin (TN)
tretinoin liposome
Tretinoin Zinc Salt
Tretinoin/all-trans retinoate
Tretinoin/all-trans retinoic acid
Tretinoina
Tretinoine
Tretinoino
Tretinoinum
Tretinon
TRETINON
Tri-Luma
UNII-1UA8E65KDZ
UNII-5688UTC01R
UPCMLD-DP097
UPCMLD-DP097:001
UPCMLD-DP097:002
Vesanoid
Vesanoid (TN)
Vesnaroid
Vitamin A acid
Vitinoin
Zinc Salt, Tretinoin
|
|
40 |
|
Bexarotene |
Approved, Investigational |
Phase 2 |
|
153559-49-0 |
82146 |
Synonyms:
153559-49-0
3-methyl-TTNEB
3-Methyl-ttneb
4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl)benzoic acid
4-(1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl)benzoic acid
4-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)benzoic acid
4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid
4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl]benzoic acid
4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid
4-[1-(3,5,5,8,8-pentamethyltetralin-2-yl)ethenyl]benzoic acid
4-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl)ethenyl]benzoic acid
4-[1-3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthaleneyl)vinyl]benzene carboxylic acid
9RA
AC1L32UG
Bexaroten
Bexarotene
Bexarotène
Bexarotene (USAN/INN)
Bexarotene [USAN]
bexaroteno
Bexaroteno
bexarotenum
Bexarotenum
BIDD:PXR0021
C095105
CHEBI:50859
CHEMBL1023
CID82146
D03106
DB00307
|
Elan brand of bexarotene
Elan brand OF bexarotene
HMS2089L14
HSDB 7453
I14-1941
LG 1069
LG100069
LG-100069
LG1069
LG69 compound
LG69 Compound
LGD 1069
LGD1069
LGD-1069
Ligand brand of bexarotene
Ligand brand OF bexarotene
LS-38306
MolPort-003-845-030
NCGC00181016-01
p-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoate
p-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid
SBB067189
Targret
Targretin
Targretin (TN)
Targretin-gel
Targretyn
Targrexin
UNII-A61RXM4375
|
|
41 |
|
Didanosine |
Approved |
Phase 2 |
|
69655-05-6 |
50599 |
Synonyms:
149409-57-4
2',3' Dideoxyinosine
2,3-dideoxyinosine
2,3-Dideoxyinosine
2',3'-Dideoxyinosine
2',3'-Dideoxyinosine & Granulocyte-macrophage colony-stimulating factor
2',3'-Dideoxyinosine & Interferon-.alpha.
2',3'-Dideoxyinosine & sCD4(soluble recombinant protein)
2',3'-Dideoxyinosine (AIDS Initiative)
2',3'-Dideoxyinosine (ddI)
2',3'-dideoxyinosine, DDI, NSC 612049, Didanosine
2'3'-DIDEOXYINOSINE
2DI
3'-Azido-3'-deoxythymidine + 2',3'-Dideoxyinosine
69655-05-6
9-((2R,5S)-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-1H-purin-6(9H)-one
9-((2R,5S)-5-(Hydroxymethyl)-tetrahydrofuran-2-yl)-1H-purin-6(9H)-one
9-((2R,5S)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-1,9-dihydro-purin-6-one
9-((2S,5R)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-9H-purin-6-ol
9-(2,3-Dideoxy-beta-D-ribofuranosyl)-6-oxopurine
9-(2,3-Dideoxy-beta-D-ribofuranosyl)hypoxanthine
9-[(2R,5R)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL]-1,9-DIHYDRO-6H-PURIN-6-ONE
9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one
9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one
9-[(2R,5S)-5-(Hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one
AC-12026
AC1L19ET
AC1L3OPK
Benzeneethanamine, 4-methoxy-3-(2-phenylethoxy)-N,N-dipropyl-, hydrochloride
Bio-0685
BMY 40900
BMY-40900
Bristol myers brand OF didanosine
Bristol myers squibb brand OF didanosine
Bristol-myers brand OF didanosine
Bristol-myers squibb brand OF didanosine
BRN 3619529
C06953
C083832
CCRIS 805
CHEBI:490877
CHEMBL1460
CID119381
CID50599
CPD000058576
D00296
D2I
D3066
DB00900
DB02392
ddI
DDI
ddI & GM-CSF
ddI & IFN-.alpha.
ddI & sCD4(rsCD4)
DdI (antiviral)
|
ddI + d4T combination
DDI and rIFN.alpha.2
ddIno
DdIno
Didanosina
Didanosina [INN-Spanish]
didanosine
Didanosine
Didanosine (JAN/USAN/INN)
Didanosine and Interferon-.alpha.-2
Didanosinum
Didanosinum [INN-Latin]
Dideoxyinosine
DIDEOXYINOSINE
Dideoxyinosine (DDI)
DRG-0016
DS-4152 & ddI
FT-0082664
HMS2051J11
HMS2089N20
HSDB 6548
Hypoxanthine ddN
Inosine, 2',3'-dideoxy- & Recombinant Interferon-.alpha.-2
Intron A & Videx
KS-1049
Listera ovata agglutinin & 2',3'-Dideoxyinosine
LOA & ddI
MLS000759469
MLS001055350
MLS001424118
MLS002154216
MolPort-002-507-371
MolPort-002-885-819
N,N-diethyl-2-(4-methoxy-3-phenethyloxyphenyl)ethanamine hydrochloride
N,N-Dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride
NCGC00090691-01
NCGC00159514-02
NCGC00159514-03
NCGC00164280-01
NE 100
NE-100
NSC 612049
NSC612049
NSC-612049
PC-SOD+ddI
S1702_Selleck
SAM001246673
SMR000058576
Sulfated polysaccharide-peptidoglycan DS-4152 & 2',3'-Dideoxyinosine
UNII-K3GDH6OH08
Videx
Videx (TN)
Videx EC
Videx EC(TM)(slow-release capsules)
Videx(TM)
ZINC13597823
|
|
42 |
|
Sargramostim |
Approved, Investigational |
Phase 2 |
|
123774-72-1, 83869-56-1 |
|
Synonyms:
123774-72-1
D05803
Leukine
Leukine (TN)
Recombinant human granulocyte-macrophage colony stimulating factor
rGM-CSF
|
rHu GM-CSF
Sargramostim
Sargramostim (genetical recombination)
Sargramostim (genetical recombination) (JAN)
Sargramostim (USAN/INN)
|
|
43 |
|
Lenograstim |
Approved, Investigational |
Phase 2 |
|
135968-09-1 |
|
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
Granulocyte colony stimulating factor 3 (CHO cell derived)
|
Granulocyte colony-stimulating factor lenograstim
Lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
|
|
44 |
|
Cidofovir |
Approved |
Phase 2 |
|
113852-37-2 |
60613 |
Synonyms:
({[(2S)-1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid
({[(S)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid
(2S)-3-Hydroxy-2-phosphonylmethoxypropyl-cytosine
(S)-(3-(4-Amino-2-oxopyrimidin-1(2H)-yl)-1-hydroxypropan-2-yloxy)methylphosphonate
(S)-(3-(4-amino-2-Oxopyrimidin-1(2H)-yl)-1-hydroxypropan-2-yloxy)methylphosphonic acid
(S)-(3-(4-Amino-2-oxopyrimidin-1(2H)-yl)-1-hydroxypropan-2-yloxy)methylphosphonic acid
(s)-[[2-(4-amino-2-oxo-1(2h)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic acid
(S)-1-(3-Hydroxy-2-phosphonomethoxypropyl)cytosine
(S)-1-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine
(S)-1-[3-hydroxy-2-(phosphonylmethoxy)-propyl]cytosine
(S)-1-[3-Hydroxy-2-(phosphonylmethoxy)propyl]cytosine
(S)-2-(4-Amino-2-oxo-1(2H)-pyrimidinyl-1-(hydroxymethyl)ethoxy)methyl phosphonic acid
(S)-HPMPC
[(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid
[(S)-2-(4-Amino-2-oxo-2H-pyrimidin-1-yl)-1-hydroxymethyl-ethoxymethyl]-phosphonate
[(S)-2-(4-Amino-2-oxo-2H-pyrimidin-1-yl)-1-hydroxymethyl-ethoxymethyl]-phosphonic acid
[[(S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic acid
1-((3-Hydroxy-2-phosphonylmethoxy)propyl)cytosine
1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine
1-(3-Hydroxy-2-phosphonylmethoxypropyl)cytosine
1-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine
1-[(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine
1-[(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]-cytosine dihydrate
113852-37-2
120362-37-0 (hydrochloride salt)
149394-66-1
AC-1666
AC1L1TLB
AC1Q6C68
AKOS005145721
|
C8H14N3O6P
CDV
CHEBI:3696
CHEMBL152
CID60613
Cidofovir
Cidofovir (anhydrous)
Cidofovir (Vistide)
Cidofovir anhydrous
Cidofovir sodium
Cidofovir, (+-)-isomer
Cidofovir, (R)-isomer
Cidofovir, sodium salt
Cidofovirum
DB00369
Forvade
GS 0504
GS 504
GS-0504
GS504
GS-504
HPMPC
HSDB 7115
LS-106432
MolPort-005-935-597
NSC742135
S1516_Selleck
UNII-768M1V522C
Vistide
Vistide, Cidofovir
|
|
45 |
|
Ixazomib |
Approved, Investigational |
Phase 2 |
|
1072833-77-2 |
|
Synonyms:
|
46 |
|
Altretamine |
Approved |
Phase 2 |
|
645-05-6 |
2123 |
Synonyms:
2,4, 6-Tris(dimethylamino)-1,3,5-triazine
2,4,6-Tris(dimethylami
2,4,6-tris(dimethylamino)-1,3,5-triazine
2,4,6-Tris(dimethylamino)-1,3,5-triazine
2,4,6-tris(dimethylamino)-s-triazine
2,4,6-Tris(dimethylamino)-s-triazine
2,4,6-Tris(dimethylamino)-S-triazine
2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine
549835_ALDRICH
645-05-6
A 8723
A0567/0026158
A8723_SIGMA
AB00052308
AC-12006
AC1L1CYX
AI3-50852
AKOS001729401
Altretamin
Altretamina
Altretamina [INN-Spanish]
altretamine
Altretamine
Altrétamine
Altretamine (USP/INN)
Altretamine [USAN:INN:BAN]
Altretamine bellon brand
Altretamine Bellon Brand
Altretamine chiesi brand
Altretamine Chiesi Brand
Altretamine wassermann brand
Altretamine Wassermann Brand
Altretaminum
Altretaminum [INN-Latin]
Bellon brand OF altretamine
Bellon Brand of Altretamine
BPBio1_001004
BRD-K67043667-001-04-1
BRN 0195058
BSPBio_000912
C9H18N6
CAS-654-05-6
CCRIS 5492
CHEBI:24564
CHEMBL1455
ChemDiv2_005185
Chiesi brand OF altretamine
Chiesi Brand of Altretamine
CID2123
CPD000058181
D006585
D02841
DB00488
DivK1c_000772
EINECS 211-428-4
ENT 50852
EU-0100083
FT-0083576
Hemel
Hexalen
Hexalen (TN)
Hexalen, Altretamine
Hexamethylmelamine
HEXAMETHYLMELAMINE
Hexastat
Hexinawas
HMM
HMS1383L15
HMS1570N14
HMS1922C05
HMS2090G17
|
HMS2092H16
HMS502G14
HSDB 7559
HTM
HXM
I06-0604
IDI1_000772
IDI1_003900
InChI=1/C9H18N6/c1-13(2)7-10-8(14(3)4)12-9(11-7)15(5)6/h1-6H
KB-913
KBio1_000772
KBio2_001788
KBio2_004356
KBio2_006924
KBio3_002042
KBioGR_001388
KBioSS_001788
Lopac0_000083
Lopac-A-8723
LS-1549
MGI pharma brand OF altretamine
MGI Pharma Brand of Altretamine
MLS000069621
MLS001076123
MolPort-002-111-210
N,N,N',N',N'',N''-hexamethyl-1,3,5-triazine-2,4,6-triamine
N~2~,N~2~,N~4~,N~4~,N~6~,N~6~-Hexamethyl-1,3,5-triazine-2,4,6-triamine
NC 195
NCGC00015100-01
NCGC00015100-02
NCGC00015100-03
NCGC00015100-06
NCGC00015100-11
NCGC00021216-03
NCGC00021216-04
NCGC00021216-05
NCGC00021216-06
NCGC00021216-07
NCI60_000871
NCI-C50259
NINDS_000772
no)-s-triazine
NSC 13875
NSC13875
NSC-13875
Prestwick0_000946
Prestwick1_000946
Prestwick2_000946
Prestwick3_000946
Rhone Poulenc Rorer Brand of Altretamine
Rhône poulenc rorer brand OF altretamine
Rhone-Poulenc Rorer Brand of Altretamine
Rhône-poulenc rorer brand OF altretamine
S1278_Selleck
SAM002564241
SMR000058181
SPBio_000754
SPBio_003071
Spectrum_001308
SPECTRUM1503065
Spectrum2_000907
Spectrum3_000951
Spectrum4_001064
Spectrum5_001092
ST086739
STK749184
UNII-Q8BIH59O7H
Wassermann brand OF altretamine
Wassermann Brand of Altretamine
WLN: T6N CN ENJ BN1&1 DN1&1 FN1&1
ZINC00000905
|
|
47 |
|
nivolumab |
Approved |
Phase 2 |
|
946414-94-4 |
|
Synonyms:
BMS-936558
MDX-1106
nivolumab
|
|
|
48 |
|
Nelfinavir |
Approved |
Phase 2 |
|
159989-64-7 |
64143 |
Synonyms:
(3S-(2(2S*,3S*),3alpha,4abeta,8abeta))-N-(1,1-Dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-3-isoquinolinecarboxamide
(3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylsulfanylbutyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide
159989-64-7
159989-65-8 (monomethane sulfonate (salt))
1ohr
1UN
2-[2-HYDROXY-3-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-4-PHENYL SULFANYL-BUTYL]-DECAHYDRO-ISOQUINOLINE-3-CARBOXYLIC ACID TERT-BUTYLAMIDE
AC1L20J6
AC-20032
AG 1343
ag1343
AG1343
AG1343 (*Mesylate salt*)
AG1346
Agouron brand OF nelfinavir mesylate
AKOS000280862
BIDD:GT0395
BIDD:PXR0143
C07257
C32H45N3O4S
CHEMBL584
CID64143
D08259
DB00220
LS-85417
Mesylate, nelfinavir
Met-SDF-1.beta. & Nelfinavir
Met-Stromal Cell-derived Factor-1.beta. (Human) & Nelfinavir
|
MLS001195634
MLS001304729
MolPort-000-883-833
MolPort-002-885-844
Monomethane sulfonate, nelfinavir
NCGC00090782-03
NCGC00090782-04
nelfinavir
Nelfinavir
Nelfinavir (INN)
Nelfinavir [BAN:INN]
Nelfinavir [INN:BAN]
Nelfinavir mesylate
NELFINAVIR MESYLATE AG1343
Nelfinavir monomethane sulfonate
Nelfinavir Monomethane Sulfonate
NFV
NLF
NSC722664
NSC747167
Roche brand OF nelfinavir mesylate
SMR000596515
Sulfonate, nelfinavir monomethane
UNII-HO3OGH5D7I
Viracept
Viracept (TM)(*Mesylate salt*)
Viracept (TN)
VRX496
|
|
49 |
|
Ipilimumab |
Approved |
Phase 2 |
|
477202-00-9 |
|
Synonyms:
BMS-734016
ipilimumab
Ipilimumab
MDX 010
|
|
|
50 |
|
Pembrolizumab |
Approved |
Phase 2 |
|
1374853-91-4 |
|
Synonyms:
|
Interventional clinical trials:
(show top 50)
(show all 111)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Randomized Comparison of Protease Inhibitor-based Versus Non-nucleoside Reverse Transcriptase Inhibitor-based Antiretroviral Therapy for Initial Treatment of Individuals With AIDS-related Kaposi's Sarcoma in Sub-Saharan Africa |
Completed |
NCT00444379 |
Phase 4 |
Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir |
2 |
A Prospective Randomized Trial Comparing the Response of HIV Kaposi's Sarcoma (KS) to HAART Versus the Combination of HAART and Chemotherapy (CXT) |
Completed |
NCT00380770 |
Phase 4 |
Generic HAART Triomune : d4T, 3TC, NVP;Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV |
3 |
Clinical and Virologic Response to HHV-8 Associated Multicentric Castleman's Disease to Valganciclovir |
Withdrawn |
NCT00361933 |
Phase 4 |
Valganciclovir |
4 |
Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Adriamycin, Bleomycin, and Vincristine (ABV) in the Treatment of Severe AIDS-Related Kaposi's Sarcoma |
Unknown status |
NCT00002318 |
Phase 3 |
Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride |
5 |
Phase III Study of Paclitaxel Versus Liposomal Doxorubicin for the Treatment of Advanced AIDS-Associated Kaposi's Sarcoma |
Completed |
NCT00003350 |
Phase 3 |
paclitaxel;pegylated liposomal doxorubicin hydrochloride |
6 |
A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe |
Completed |
NCT00834457 |
Phase 2, Phase 3 |
abacavir/3TC/zidovudine;abacavir /3TC plus ritonavir boosted lopinavir |
7 |
Double-Blind Randomized Evaluation of Clinical Benefits of DOXIL in Patients With AIDS-Related Kaposi's Sarcoma Treated With DOXIL or DaunoXome |
Completed |
NCT00002985 |
Phase 3 |
daunorubicin hydrochloride;pegylated liposomal doxorubicin hydrochloride |
8 |
A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma. |
Completed |
NCT00002093 |
Phase 3 |
Daunorubicin (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride |
9 |
A Phase III Randomized Placebo Controlled and Double Blinded Study of IM862 for Patients With Muco-Cutaneous AIDS Associated Kaposi's Sarcoma |
Completed |
NCT00002445 |
Phase 3 |
IM862 |
10 |
Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma |
Completed |
NCT00002105 |
Phase 3 |
Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate |
11 |
A Placebo-Controlled Trial To Evaluate Azidothymidine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients With AIDS-Associated Kaposi's Sarcoma |
Completed |
NCT00000994 |
Phase 3 |
Zidovudine |
12 |
Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma. |
Completed |
NCT00002147 |
Phase 3 |
Doxorubicin hydrochloride (liposomal) |
13 |
Open Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma |
Completed |
NCT00002319 |
Phase 3 |
Doxorubicin hydrochloride (liposomal) |
14 |
Treatment of HIV-Related Kaposi's Sarcoma and Stage I-III Slow-Proliferative Disease With Highly Active Antiretroviral Therapy (HAART) |
Unknown status |
NCT00003419 |
Phase 2 |
|
15 |
Suppression of Oral Shedding of Human Herpesvirus 8 (HHV-8) With Valganciclovir |
Completed |
NCT00194467 |
Phase 2 |
valganciclovir;placebo |
16 |
Pilot Study of Tocilizumab in Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV) - Associated Multicentric Castleman Disease |
Completed |
NCT01441063 |
Phase 2 |
Zidovudine;Tocilizumab;Valganciclovir (VGC) |
17 |
Treatment of Classical Kaposi Sarcoma With Nicotine Dermal Patch: A Phase II Trial |
Completed |
NCT00295984 |
Phase 2 |
nicotine |
18 |
A Phase I/II Study of Lenalidomide in Patients With AIDS-Associated Kaposi's Sarcoma |
Completed |
NCT01057121 |
Phase 1, Phase 2 |
Lenalidomide |
19 |
A Phase II Trial of Topical Halofuginone in Patients With HIV Related Kaposi's Sarcoma |
Completed |
NCT00064142 |
Phase 2 |
halofuginone hydrobromide |
20 |
Phase I/II Pilot Study of Interleukin-12 in Patients With AIDS-Associated Kaposi's Sarcoma |
Completed |
NCT00019188 |
Phase 1, Phase 2 |
interleukin-12 |
21 |
An Open-Label Pilot Phase 2 Study to Investigate Efficacy, Safety, and Intratumoral Kinetics of ALDOXORUBICIN in HIV-Infected Patients With Kaposi's Sarcoma |
Completed |
NCT02029430 |
Phase 2 |
aldoxorubicin |
22 |
A Phase II Trial With the HIV Protease Inhibitor Indinavir for the Treatment of Classical Kaposi's Sarcoma |
Completed |
NCT00362310 |
Phase 2 |
indinavir |
23 |
Phase II Study of Intravenous Recombinant Humanized Anti-Vascular Endothelial Cell Growth Factor Antibody (Bevacizumab) in Classical (HIV-Negative) and in AIDS-Associated Kaposi's Sarcoma |
Completed |
NCT00055237 |
Phase 2 |
|
24 |
Phase II Trial for the Treatment of Advanced Classical Kaposi's Sarcoma With the HIV Protease Inhibitor Indinavir in Combination With Chemotherapy |
Completed |
NCT01067690 |
Phase 2 |
Indinavir in association with Vinblastina +/- Bleomicina |
25 |
Evaluation of Technetium Tc 99m Tilmanocept Localization, Retention, and Distribution in Primary Cutaneous Kaposi's Sarcoma (KS) and Lymphatic Drainage From KS Lesions by SPECT/CT Imaging. |
Completed |
NCT02201420 |
Phase 2 |
Tc 99m tilmanocept |
26 |
Pilot Study to Evaluate the Potential Interactions Between Paclitaxel and Protease Inhibitors in Patients With AIDS-Related Kaposi's Sarcoma |
Completed |
NCT00003008 |
Phase 2 |
indinavir sulfate;nelfinavir mesylate;paclitaxel;ritonavir;saquinavir mesylate |
27 |
Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma |
Completed |
NCT00002259 |
Phase 2 |
Mitoxantrone hydrochloride |
28 |
Phase II Evaluation of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma |
Completed |
NCT00002212 |
Phase 2 |
Bexarotene |
29 |
A Phase II Safety and Activity Study of Ritonavir in the Treatment of HIV-Associated Cutaneous Kaposi's Sarcoma |
Completed |
NCT00002366 |
Phase 2 |
Ritonavir |
30 |
Comparison Study of Liposomal Doxorubicin With or Without Bleomycin and Vincristine for the Treatment of Advanced AIDS-Associated Kaposi's Sarcoma |
Completed |
NCT00001059 |
Phase 2 |
Doxorubicin hydrochloride (liposomal);Filgrastim;Bleomycin sulfate;Vincristine sulfate |
31 |
Phase II Study of Weekly Doxorubicin Treatment of AIDS Associated Kaposi's Sarcoma |
Completed |
NCT00000996 |
Phase 2 |
Doxorubicin hydrochloride |
32 |
A Phase I-II Trial Of BMS-275291 In Patients With HIV-Related Kaposi's Sarcoma |
Completed |
NCT00024024 |
Phase 1, Phase 2 |
rebimastat |
33 |
A Phase II Study of Liposomal Doxorubicin and Interleukin-12 in AIDS-Associated Kaposi's Sarcoma Followed by Chronic Administration of Interleukin-12 |
Completed |
NCT00020449 |
Phase 2 |
paclitaxel;pegylated liposomal doxorubicin hydrochloride |
34 |
A Phase II Study of Oral Ro 24-7429 (Tat Antagonist) in Patients With HIV-Related Kaposi's Sarcoma |
Completed |
NCT00002314 |
Phase 2 |
Ro 24-7429 |
35 |
Phase II Evaluation of Oral ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma. |
Completed |
NCT00002188 |
Phase 2 |
Alitretinoin |
36 |
A Randomized Phase II Trial to Determine the Safety, Tolerance, and Efficacy of Two Doses of Interferon Alfa-2b Combined With Didanosine in Patients With Kaposi's Sarcoma |
Completed |
NCT00001114 |
Phase 2 |
Interferon alfa-2b;Didanosine |
37 |
A Phase II Trial Of Imatinib Mesylate (Gleevec) In Patients With HIV Related Kaposi's Sarcoma |
Completed |
NCT00090987 |
Phase 2 |
imatinib mesylate |
38 |
A Multicenter, Open-Label, Phase II Study of SU5416 in Patients With Cutaneous AIDS-Related Kaposi's Sarcoma |
Completed |
NCT00005042 |
Phase 2 |
semaxanib |
39 |
PHASE II PROTOCOL WITH LABORATORY CORRELATES OF 1-[(S)-3-HYDROXY-2-(PHOSPHOMETHOXY)PROPYL]CYTOSINE DIHYDRATE(CIDOFOVIR) IN PATIENTS WITH KAPOSI'S SARCOMA (KS) |
Completed |
NCT00019240 |
Phase 2 |
cidofovir |
40 |
A PHASE II STUDY OF ORAL THALIDOMIDE FOR PATIENTS WITH HIV INFECTION AND KAPOSI'S SARCOMA |
Completed |
NCT00019123 |
Phase 2 |
thalidomide |
41 |
A Multicenter, Open-Label, Phase II Study of SU5416 in Patients With Therapy-Refractory Cutaneous AIDS-Related Kaposi's Sarcoma |
Completed |
NCT00005931 |
Phase 2 |
SU5416 |
42 |
A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma |
Completed |
NCT00002131 |
Phase 2 |
Vesnarinone |
43 |
Paclitaxel in Advanced Refractory Kaposi's Sarcoma (AIDS-KS): A Phase II Trial of Paclitaxel From Baker Norton Pharmaceuticals |
Completed |
NCT00002189 |
Phase 2 |
Paclitaxel |
44 |
Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary. |
Completed |
NCT00002167 |
Phase 2 |
Tin ethyl etiopurpurin |
45 |
Phase II Study of Zidovudine and Recombinant Alpha-2A Interferon in the Treatment of Patients With AIDS-Associated Kaposi's Sarcoma |
Completed |
NCT00000687 |
Phase 2 |
Interferon alfa-2a;Zidovudine |
46 |
Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressed AIDS-Related Kaposi's Sarcoma After Systemic Chemotherapy |
Completed |
NCT00000807 |
Phase 2 |
Etoposide |
47 |
A Phase 2 Trial of Ixazomib for Kaposi Sarcoma |
Recruiting |
NCT04305691 |
Phase 2 |
Ixazomib Citrate |
48 |
A Phase II Study of sEphB4-HSA in Kaposi Sarcoma |
Recruiting |
NCT02799485 |
Phase 2 |
|
49 |
Phase I/II of NHS-IL12 Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma |
Recruiting |
NCT04303117 |
Phase 1, Phase 2 |
NHS-IL12;M7824 |
50 |
A Phase II Multicenter Study of Pomalidomide Monotherapy in HIV-Positive Individuals With Kaposi Sarcoma (KS) in Sub-Saharan Africa (SSA) |
Recruiting |
NCT03601806 |
Phase 2 |
Pomalidomide |
Inferred drug relations via
UMLS
71
/
NDF-RT
51
:
alitretinoin
doxorubicin hydrochloride liposome
Etoposide
etoposide phosphate
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
|
Interferons
Paclitaxel
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b
Vinblastine
Vinblastine Sulfate
|
|